Results 21 to 30 of about 51,615 (305)

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Haematologica, 2015
Although numerous recent publications have demonstrated interest in multiparameter flow cytometry in the investigation of myelodysplastic disorders, it is perceived by many laboratory hematologists as difficult and expensive, requiring a high level of ...
Valérie Bardet, Orianne Wagner-Ballon, Julien Guy, Céline Morvan, Camille Debord, Franck Trimoreau, Emmanuel Benayoun, Nicolas Chapuis, Nicolas Freynet, Cédric Rossi, Stéphanie Mathis, Marie-Pierre Gourin, Andréa Toma, Marie C. Béné, Jean Feuillard, Estelle Guérin   +15 more
doaj   +1 more source

Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review

Hemato, 2022
Extramedullary hematopoiesis is rarely seen in patients with myelodysplastic syndromes, and its clinical characterizations are not well-defined.
Chen Wang, Yiyun Shi
doaj   +1 more source

Clonal architecture of secondary acute myeloid leukemia [PDF]

, 2012
BACKGROUND: The myelodysplastic syndromes are a group of hematologic disorders that often evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie progression from the myelodysplastic syndromes to secondary AML are not well ...
Abbott, Rachel, Chen, Ken, Ding, Li, DiPersio, John F, Dooling, David, Eades, William, Fan, Xian, Frater, John L, Fulton, Robert, Graubert, Timothy A, Grillot, Marcus, Heath, Sharon, Kalicki-Veizer, Joelle, Koboldt, Daniel C, Larson, David E, Ley, Timothy J, Link, Daniel C, Magrini, Vincent, Mardis, Elaine R, McLellan, Michael D, O\u27Laughlin, Michelle, Schmidt, Heather, Shao, Jin, Shen, Dong, Tomasson, Michael, Walter, Matthew J, Westervelt, Peter, Wilson, Richard K, Witowski, Sarah   +28 more
core   +2 more sources

Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes

Haematologica, 2012
Background Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Survivin is a member of the inhibitor of apoptosis family and suppresses apoptosis.
Akira Yoshida, Kouichi Zokumasu, Yuji Wano, Takahiro Yamauchi, Shin Imamura, Kazutaka Takagi, Shinji Kishi, Yoshimasa Urasaki, Kaoru Tohyama, Takanori Ueda   +9 more
doaj   +1 more source

Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else

Revista Brasileira de Hematologia e Hemoterapia, 2014
Although myelodysplastic syndromes have a clear definition in theory, the morphologic dysplasia associated with ineffective hematopoiesis may be subtle and difficult to recognize and can commonly be mimicked by systemic conditions, such as infections ...
Paula de Melo Campos, Fabiola Traina, Irene Lorand-Metze, Sara Teresinha Olalla Saad   +3 more
doaj   +1 more source

TP53 mutations in myelodysplastic syndromes with deletion of 5q [PDF]

, 2009
The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant bone marrow disorders characterized by peripheral cytopenia(s) and increased risk of progression to acute myeloid leukemia (AML).
Boultwood, Jacqueline, Göhring, G, Hellström-Lindberg, E, Jädersten, M, Pellagatti, A, Porwit, A, Saft, L, Schlegelberger, B, Wainscoat, JS   +8 more
core   +2 more sources

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax

Case Reports in Hematology, 2020
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia.
Waqas Jehangir, Alexander Karabachev, Taimoor Jahangir, Elvira Umyarova   +3 more
doaj   +1 more source

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

Haematologica, 2010
Background There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice.Design and Methods We conducted a cross-sectional study of all patients with myelodysplastic syndromes attending 74 ...
Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Emmanuel Raffoux, Bruno Quesnel, Agnes Guerci, François Dreyfus, Sabine Brechignac, Christian Berthou, Thomas Prebet, Yosr Hicheri, Maya Hacini, Jacques Delaunay, Marie-Pierre Gourin, Jean-Marie Camo, Hacene Zerazhi, Anne-Laure Taksin, Laurence Legros, Bachra Choufi, Pierre Fenaux   +19 more
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

Haematologica, 2013
Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia.
Alan H. Shih, Stephen S. Chung, Emily K. Dolezal, Su-Jiang Zhang, Omar I. Abdel-Wahab, Christopher Y. Park, Stephen D. Nimer, Ross L. Levine, Virginia M. Klimek   +8 more
doaj   +1 more source